Tags

Type your tag names separated by a space and hit enter

A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure.
Surv Ophthalmol 2004; 49 Suppl 1:S19-25SO

Abstract

In glaucoma and ocular hypertension, clinically relevant intraocular pressure lowering due to a new medication is frequently defined as at least a 15% or 20% reduction from baseline intraocular pressure. This report compares the percentages of treated patients achieving such reductions in intraocular pressure after 6 months of treatment with bimatoprost or latanoprost. In the previously published study (Noecker et al: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135:55-63, 2003), patients with glaucoma or ocular hypertension were randomly assigned to once-daily treatment with bimatoprost 0.03% (n=133) or latanoprost 0.005% (n=136), after washout of any previous glaucoma medications. The primary outcome measure of that study was mean change from baseline intraocular pressure. The secondary, post hoc analysis presented here compares the diurnal and long-term responder rates observed with bimatoprost and latanoprost patients. Diurnal responders were defined as patients who achieved at least a 15% or 20% reduction from baseline intraocular pressure at each of the three timepoints (8 am, 12 pm, and 4 pm) on a given visit. At week 1 and months 1, 3, and 6, in the bimatoprost group, 70.7-81.2% of patients achieved at least a 15% reduction in IOP at each timepoint, and 57.9-68.4% achieved at least a 20% reduction. Significantly fewer patients receiving latanoprost achieved a 15% or a 20% decrease in IOP at each timepoint: 48.5-61.8% of patients achieved at least a 15% decrease and 36.0-47.1% achieved at least a 20% decrease. (P< or =.007). The data presented here suggest that patients using bimatoprost are more likely than patients using latanoprost to achieve intraocular pressure reductions of at least 15% or 20% from baseline throughout the day.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15016558

Citation

Choplin, Neil, et al. "A Randomized, Investigator-masked Comparison of Diurnal Responder Rates With Bimatoprost and Latanoprost in the Lowering of Intraocular Pressure." Survey of Ophthalmology, vol. 49 Suppl 1, 2004, pp. S19-25.
Choplin N, Bernstein P, Batoosingh AL, et al. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv Ophthalmol. 2004;49 Suppl 1:S19-25.
Choplin, N., Bernstein, P., Batoosingh, A. L., & Whitcup, S. M. (2004). A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Survey of Ophthalmology, 49 Suppl 1, pp. S19-25.
Choplin N, et al. A Randomized, Investigator-masked Comparison of Diurnal Responder Rates With Bimatoprost and Latanoprost in the Lowering of Intraocular Pressure. Surv Ophthalmol. 2004;49 Suppl 1:S19-25. PubMed PMID: 15016558.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. AU - Choplin,Neil, AU - Bernstein,Paula, AU - Batoosingh,Amy L, AU - Whitcup,Scott M, AU - ,, PY - 2004/3/16/pubmed PY - 2004/4/24/medline PY - 2004/3/16/entrez SP - S19 EP - 25 JF - Survey of ophthalmology JO - Surv Ophthalmol VL - 49 Suppl 1 N2 - In glaucoma and ocular hypertension, clinically relevant intraocular pressure lowering due to a new medication is frequently defined as at least a 15% or 20% reduction from baseline intraocular pressure. This report compares the percentages of treated patients achieving such reductions in intraocular pressure after 6 months of treatment with bimatoprost or latanoprost. In the previously published study (Noecker et al: A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 135:55-63, 2003), patients with glaucoma or ocular hypertension were randomly assigned to once-daily treatment with bimatoprost 0.03% (n=133) or latanoprost 0.005% (n=136), after washout of any previous glaucoma medications. The primary outcome measure of that study was mean change from baseline intraocular pressure. The secondary, post hoc analysis presented here compares the diurnal and long-term responder rates observed with bimatoprost and latanoprost patients. Diurnal responders were defined as patients who achieved at least a 15% or 20% reduction from baseline intraocular pressure at each of the three timepoints (8 am, 12 pm, and 4 pm) on a given visit. At week 1 and months 1, 3, and 6, in the bimatoprost group, 70.7-81.2% of patients achieved at least a 15% reduction in IOP at each timepoint, and 57.9-68.4% achieved at least a 20% reduction. Significantly fewer patients receiving latanoprost achieved a 15% or a 20% decrease in IOP at each timepoint: 48.5-61.8% of patients achieved at least a 15% decrease and 36.0-47.1% achieved at least a 20% decrease. (P< or =.007). The data presented here suggest that patients using bimatoprost are more likely than patients using latanoprost to achieve intraocular pressure reductions of at least 15% or 20% from baseline throughout the day. SN - 0039-6257 UR - https://www.unboundmedicine.com/medline/citation/15016558/A_randomized_investigator_masked_comparison_of_diurnal_responder_rates_with_bimatoprost_and_latanoprost_in_the_lowering_of_intraocular_pressure_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0039625703001917 DB - PRIME DP - Unbound Medicine ER -